Plasma and Urine Indoleamine 2,3-Dioxygenase Activity: Promising Biomarkers for Chronic Kidney Disease and Inflammation Status
Hao Hong,Suya Zhou,Haimin Shi,Ming Li
DOI: https://doi.org/10.2147/JIR.S378594
IF: 4.5
2022-09-08
Journal of Inflammation Research
Abstract:Hao Hong, 1 Suya Zhou, 2 Haimin Shi, 3 Ming Li 3 1 Intensive Care Unit, The First Affiliated Hospital of Soochow University, Soochow, People's Republic of China; 2 Laboratory Nephrology, Department of Nephrology, Jinshan Hospital of Fudan University, Shanghai, People's Republic of China; 3 Laboratory Nephrology, The First Affiliated Hospital of Soochow University, Soochow, People's Republic of China Correspondence: Ming Li, Tel +86 13656237709, Fax +0512-67972681, Email Purpose: Our aim was to determine the relationship between plasma and urine indoleamine 2.3-dioxygenase (IDO) activity and stage of chronic kidney disease (CKD). Patients and Methods: Demographic and clinical parameters, including plasma and urine IDO activity, were recorded in 47 CKD patients and 30 controls. One-way ANOVA with the least significant difference method was used to compare means of variables that had normal distributions and homogeneous variance. Variables with non-normal distributions were log-transformed and compared using the rank sum test Pearson or Spearman correlation coefficients were determined. Binary logistic regression and ordinal logistic regression were used to identify independently significant factors. Receiver operating characteristic (ROC) analysis was performed. Results: The control group had higher levels of hemoglobin and albumin and lower levels of creatinine and blood urea nitrogen (BUN; all P < 0.01). The level of highly sensitive C reactive protein (hs-CRP) increased as CKD stage increased ( P< 0.01). Plasma and urine IDO activity were positively correlated (r=0.7, P< 0.01). Plasma IDO activity correlated with age, creatinine, BUN, triglycerides, uric acid, albumin, and hemoglobin (all P< 0.05); urine IDO activity correlated with age, BMI, creatinine, BUN, and hemoglobin (all P< 0.05). There were positive correlations of hs-CRP level with plasma IDO activity and urine IDO activity (both P< 0.01). After adjusting for CKD-related factors, plasma IDO activity, urine IDO activity, and hs-CRP were independent risk factors for CKD (all P< 0.05). Ordinal logistic regression also indicated that plasma and urine IDO activity were significantly associated with CKD stage. ROC analysis indicated that plasma and urine IDO activity were good predictors of CKD and distinguished different stages of CKD. There was a strong correlation between plasma IDO activity and inflammatory status in patients with CKD (OR=1258.908, P< 0.01). Conclusion: Plasma and urine IDO activity have potential use as biomarkers for early-stage CKD, progression of CKD, and inflammation status. Keywords: tryptophan rate-limiting enzyme, inflammatory, hs-CRP, liquid chromatography-mass spectrometry Chronic Kidney Disease (CKD) is a major threat to public health throughout the world, and it has a prevalence of about 10.8% in China. 1 Thus, CKD is one of the most common non-communicable chronic diseases, is associated with high morbidity, and is responsible for extensive healthcare costs. As CKD progresses, patients experience significant somatic symptoms, reduced health-associated life quality, and extensive lifestyle limitations. 2,3 Clinicians commonly measure the serum levels of creatinine and cystatin C to assess CKD severity. However, these markers are not sensitive enough for the early diagnosis of CKD and do not have high diagnostic specificity. The pathogenesis and progression of CKD is complex and incompletely elucidated, but CKD is related to many factors, such as the chronic inflammatory state and immune disorders. Therefore, it is very important to develop improved methods for early detection of CKD and to further examine the mechanism of CKD progression. Indoleamine 2.3-dioxygenase (IDO) is a heme-containing monomeric enzyme that catalyzes the conversion of tryptophan (TRP) into kynurenine (KYN) and is the rate-limiting enzyme in the TRP-KYN pathway. IDO has immunomodulatory effects due to its important role in tryptophan metabolism. These effects include down-regulation of T cells, control of inflammation, and immune tolerance. Recent studies of cancer patients suggested that innate responses during tumorigenesis can up-regulate IDO, and that IDO can increase the response to immunotherapy. For example, Thüring et al reported that urine IDO had prognostic value in patients undergoing radical prostatectomy. These same mechanisms are also important in the development and progression of CKD. 4,5 Huttunen et al found that the level of IDO was closely related to inflammatory status and mortality in patients with sepsis. 6 Some studies in China found that the inhi -Abstract Truncated-
immunology